Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome

Lancet. 1987 Apr 4;1(8536):763-5. doi: 10.1016/s0140-6736(87)92796-6.

Abstract

A randomised therapeutic trial of 13-cis-retinoic acid was carried out in 70 patients with myelodysplastic syndrome having 5% or fewer marrow blast cells. Among non-sideroblastic patients the 1-year survival in the treated group was 77%, compared with 36% in the control group. There were too few deaths among patients with sideroblastic anaemia to allow any effect of therapy on survival to be evaluated.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Sideroblastic / drug therapy
  • Anemia, Sideroblastic / mortality
  • Clinical Trials as Topic
  • Female
  • Humans
  • Isomerism
  • Isotretinoin
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / mortality
  • Random Allocation
  • Tretinoin / therapeutic use*

Substances

  • Tretinoin
  • Isotretinoin